About Broad Street Alerts:
Big opportunities in Small Cap’s right now
Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our members in December 2015 alone.
March 7th, 2016-(NASDAQ: FREE) opened at $.02 hit a high of $.05/share within 3 days for gains of 150% for our members.
March 3rd, 2016 (NASDAQ: BCEI) opened at $1,13 hit a high of $3.38 within 3 days for 199% gains for our members.
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100% in gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business. We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Due Diligence Report: Collaboration with Ceiling Biosciences; Earnings Surprise Upcoming
Summary:
Amedica Corporation, incorporated on December 10, 1996, is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer focused on using its silicon nitride technology platform to develop, manufacture and sell a range of medical devices. The Company markets spinal fusion products and are developing products for use in total hip and knee joint replacements. The Company markets and sells its products to surgeons and hospitals in the United States and select markets in Europe and South America.
The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. The Company’s Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Cervical and Corpectomy. In addition to its silicon nitride-based spinal fusion products, the Company markets a line of non-silicon nitride spinal fusion products, which allows it to provide surgeons and hospitals with a range of products. These additional products are complementary to its fusion products and are designed for the treatment of deformity and degenerative spinal procedures. It is also developing multiple silicon nitride components for use in its total hip and knee replacement product candidates.
The Company produces silicon nitride for use in its commercial products and product candidates in four forms. Solid Silicon Nitride (MC2) is a fully dense, load-bearing solid and is used for devices, including interbody spinal fusion devices, hip and knee replacement implants and dental implants. Porous Silicon Nitride (CSC) has a chemical composition that is identical to that of MC2, the CSC form of silicon nitride has a porous structure, which is engineered to mimic cancellous bone, the spongy like bone tissue that makes up the interior of human bones. Composite Silicon Nitride is a combination of MC2 and CSC forms of silicon nitride. This composite form of silicon nitride is used in interbody spinal fusion devices and can be used in components for total hip and knee replacement implants. Silicon Nitride Coating is a chemical composition that can be applied as an adherent coating to metallic substrates, including cobalt-chromium, titanium and steel alloys.
Amedica Corporation has a current market capitalization of $107.71 with 106.35 M outstanding shares. Its daily average volume traded is 0.76 M shares.
Financial Highlights (Q3 2015):
Revenue: 4.83 M
Gross Profit: 3.19 M
Net Income: -10.13 M
Cash and Cash Equivalents: 11.27 M
Total Debt: 19.97 M
Recent News and Analysis:
The company recently announced collaboration with Celling Biosciences, a leader in autologous cellular therapy technologies, to research and develop biologically enhanced implants. As part of the initial phase of the collaboration, Celling Biosciences’ team of scientists produced research indicating mesenchymal stem cells can be optimized and proliferate when using silicon nitride compared to the current PEEK and titanium biomaterial standards. Results from the recent in vivo scientific study show that Amedica’s proprietary silicon nitride composition significantly outperformed PEEK in attachment testing of mesenchymal stem cells. Amedica’s unique silicon nitride biomaterial contains natural nano-surface topography and chemistry that play an active role in implant integration, which current trends in surface modification efforts have not replicated. The results of the study suggest the microenvironment of silicon nitride promotes better cell adhesion and compatibility with five times greater cell adhesion as compared to the PEEK material used. With the initial research phase completed, Celling Biosciences will then translate the early findings to clinical trials in spinal and orthopedic applications. This collaborative research will further define the clinical advantages of silicon nitride in combination with stem cell-based therapies. Based on further scientific findings, the intellectual property from both partners could be leveraged to create innovative solutions that promote a robust nanotechnology. The company also announced that it will release financial results for its fourth quarter and full-year 2015 on Thursday, March 17, 2016, after the market closes.
Conclusions:
Analysts are looking for earnings per share of $-0.60 on revenue of $4.75M. The company has registered negative earnings surprises in four of the last four quarters with an average of -54.38%. Amedica Corporation reported Q3 EPS of $-2.10, missing the consensus estimate of $-0.90. Revenue came in at $4.84M, which was below the consensus $5.00M projection. Looking back further, it reported an increase in revenues to $4.78M in Q2 from $4.74M in Q1. The consensus estimate was of $4.70M and $5.55M, respectively. Expectation for EPS is high from analysts, and should AMDA meet these expectations, a new upward trend may form.
Sources:
- http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=AMDA.O
- https://www.google.ca/finance?q=NASDAQ%3AAMDA&hl=en&gl=ca&ei=RHbjVqmcDsSm2AaPup6gCg
- http://finance.yahoo.com/q/hp?s=AMDA+Historical+Prices
- http://finance.yahoo.com/news/amedica-celling-biosciences-collaborate-biologically-141500100.html
- http://finance.yahoo.com/news/amedica-celling-biosciences-collaborate-biologically-141500100.html
Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it, and I have no business relationship with any company whose stock is mentioned in the article. I reserve the right to sell the redistribution rights to this report for up to two hundred fifty dollars/news source.
The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Robert Borowski, MSc. to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor’s particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.
DISCLAIMER
Broad Street Alerts has compensated the author of this report up to two hundred and fifty dollars for the redistribution rights for a period of up to 30 days.
BroadStreetAlerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We have not been compensated in any form by any entity for this report. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.
